# Kisspeptin

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/kisspeptin (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A hypothalamic neuropeptide that stimulates GnRH release and is being investigated for fertility and hypogonadism.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/kisspeptin

\*\*Kisspeptin-10 (KP-10)\*\* · Hormone & GH · Moderate Evidence · Research Only A hypothalamic neuropeptide that stimulates GnRH release and is being investigated for fertility and hypogonadism. ### Description Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, produced primarily in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus. The most studied form for research purposes is Kisspeptin-10 (KP-10), the C-terminal decapeptide. Kisspeptin is recognized as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis — without kisspeptin signaling, puberty does not occur and reproductive function is absent. It has been investigated in Phase I and II clinical trials for hypogonadotropic hypogonadism, female infertility, and as a diagnostic tool for HPG axis assessment. Kisspeptin levels are regulated by sex steroids (both positive and negative feedback), metabolic status (leptin, insulin), and stress, making it a key integrator of reproductive and metabolic signaling. ### Key Characteristics - \*\*Molecular Formula:\*\* C63H83N15O14 - \*\*Molecular Weight:\*\* 1302.4 Da - \*\*Half-Life:\*\* ~28 minutes - \*\*Administration Routes:\*\* Subcutaneous injection, Intravenous (research) - \*\*Typical Dose:\*\* 1–10 mcg/kg - \*\*Frequency:\*\* Pulsatile (every 90 minutes) or as directed - \*\*Cycle Length:\*\* 4–8 weeks ### Investigated Benefits - Stimulates LH and FSH release - Potential treatment for hypogonadotropic hypogonadism - Fertility enhancement - Testosterone optimization - Preserves HPG axis function \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action Kisspeptin binds to the KISS1 receptor (KISS1R, also known as GPR54) — a Gq/11-coupled GPCR expressed on GnRH neurons in the hypothalamus. KISS1R activation triggers the PLC-IP3-DAG pathway, increasing intracellular calcium and depolarizing GnRH neurons, which triggers pulsatile GnRH release into the hypothalamic-pituitary portal circulation. GnRH then binds to GnRH receptors on gonadotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile secretion of LH and FSH. LH acts on Leydig cells in the testes to stimulate testosterone synthesis, while FSH supports spermatogenesis and follicular development. The pulsatile nature of kisspeptin-GnRH-LH signaling is critical: continuous kisspeptin stimulation leads to receptor desensitization and gonadotropin suppression, while pulsatile administration maintains or restores reproductive function. ### Dosing Protocol - \*\*Typical Dose:\*\* 1–10 mcg/kg - \*\*Frequency:\*\* Pulsatile (every 90 minutes) or as directed - \*\*Cycle Length:\*\* 4–8 weeks - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Pulsatile administration mimics natural GnRH release. Requires careful monitoring of LH, FSH, and sex hormones. ### Reconstitution Guide Add 1 mL bacteriostatic water to 1 mg vial → 1000 mcg/mL ### Storage Information Lyophilized: refrigerate. Reconstituted: refrigerate and use within 14 days. ### Quality & Sourcing Standards When sourcing Kisspeptin for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Phase II trials for hypogonadotropic hypogonadism 2. Demonstrated LH and testosterone stimulation in human studies 3. Phase I/II trials for female infertility ongoing ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.